Immune Pharmaceuticals Partners in Antibody Development
By

By
Immune Pharmaceuticals, a New York-headquartered clinical-stage biopharmaceutical company focused on inflammatory diseases and cancers, has entered into an exclusive sub-license agreement with SATT Sud-Est, a Marseille, France-based technology transfer office,…

Beximco Forms Med Products Joint Venture
By

By
Beximco Pharmaceuticals, a Dhaka, Bangladesh-headquartered manufacturer of generic pharmaceuticals and active pharmaceutical ingredients, has created a joint venture with BioCare Manufacturing, a Petaling Jaya, Selangor, Malaysia -based pharmaceutical company. Under…

Zymeworks Opens R&D Lab for ADCs
By

By
Zymeworks, a Vancouver, Canada-headquartered clinical-stage biopharmaceutical company, has opened a new 10,000-square-foot laboratory facility in Vancouver, Canada, for developing antibody drug conjugates (ADCs). The new lab will provide the company…

Biocon to Supply Insulin to Malaysia
By

By
Biocon, a Bangalore, India-headquartered biopharmaceuticals company, has been awarded a three-year, Malaysia ringgit 300 million ($68 million) contract by the Ministry of Health (MoH) in Malaysia for supplying recombinant human…

EMA Advisory Committee Recommends Amgen’s Humira Biosimilar
By

By
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of an Amgen adalimumab biosimilar, Solymbic, for all…

Novo Nordisk Invests $143 Million in Diabetes Center
By

By
Novo Nordisk has formed a research collaboration with the University of Oxford  in the UK for the development of Type 2 diabetes under which Novo Nordisk will invest around Danish…

Incyte in $480-Million Arginase Inhibitor Pact
By

By
Incyte, a Wilmington, Delaware-based biopharmaceutical company, has formed a collaboration and license agreement with Calithera Biosciences, a South San Franciso-headquartered clinical-stage pharmaceutical company focused on small-molecule drugs for cancer, to…

Mylan Recalls Four Doses of Brain-Tumor Drug
By

By
Mylan has issued a voluntarily Class II recall of four dosage forms of temozolomide capsules, a chemotherapy brain-tumor drug. Mylan initiated the recall in December 2016 for the 100-mg, 140-mg,…

Pfizer Leads Pipeline News
By

By
A roundup of the latest market developments from the pipelines of the pharmaceutical majors and other related news, featuring news from Pfizer. Editor’s Note: This article is updated on a…

Adma to Acquire Immune Drug Assets
By

By
Adma Biologics, a Ramsey, New Jersey-based late-stage biopharmaceutical company focused on specialty plasma-based biologics, has signed a definitive agreement to acquire certain manufacturing and therapy-related assets in relation to an…